For research use only. Not for therapeutic Use.
BAY-0069（Cat No.:I042622）is an experimental compound under investigation for its potential in treating various cancers and inflammatory diseases. It is designed to target specific molecular pathways involved in tumor progression, immune modulation, and cell survival. BAY-0069 has shown promise in preclinical studies, demonstrating its ability to inhibit cancer cell proliferation and promote immune response activation. Ongoing research is focused on evaluating its safety, pharmacokinetics, and therapeutic potential in clinical settings, particularly for tumors that are resistant to standard therapies. BAY-0069 represents a novel approach to targeted cancer treatment and immune modulation.
| CAS Number | 420826-65-9 |
| Synonyms | 2-bromo-N-[2-(4-ethylphenyl)-1,3-benzoxazol-5-yl]-5-nitrobenzamide |
| Molecular Formula | C22H16BrN3O4 |
| Purity | ≥95% |
| IUPAC Name | 2-bromo-N-[2-(4-ethylphenyl)-1,3-benzoxazol-5-yl]-5-nitrobenzamide |
| InChI | InChI=1S/C22H16BrN3O4/c1-2-13-3-5-14(6-4-13)22-25-19-11-15(7-10-20(19)30-22)24-21(27)17-12-16(26(28)29)8-9-18(17)23/h3-12H,2H2,1H3,(H,24,27) |
| InChIKey | BJSIVXYQIGFUCG-UHFFFAOYSA-N |
| SMILES | CCC1=CC=C(C=C1)C2=NC3=C(O2)C=CC(=C3)NC(=O)C4=C(C=CC(=C4)[N+](=O)[O-])Br |
